UK markets close in 5 hours 17 minutes

Valneva SE (0OB3.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.2160-0.1336 (-3.99%)
As of 10:32AM BST. Market open.
Full screen
Previous close3.3496
Open3.2380
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.1780 - 3.2960
52-week range2.8190 - 7.8420
Volume9,159
Avg. volume61,823
Market cap288.618M
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)-0.7060
Earnings date13 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

    Saint-Herblain (France), June 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“the Meeting”) to be held on June 26, 2024 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France). The Preliminary Notice of Meeting – including the agenda, the draft resolutions proposed by the Board of Directors, and instructions f

  • GlobeNewswire

    VALNEVA - Declaration of shares and voting rights: May 31, 2024

    VALNEVA Declaration of shares and voting rights May 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: June 4, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was re

  • Globe Newswire

    Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

    Saint-Herblain (France), June 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that management will participate at several upcoming investor conferences in the United States and Europe during June 2024. Valneva will present and meet with global institutional investors to discuss VLA15, the world’s leading Lyme Disease vaccine candidate, in Phase 3 development and partnered with Pfizer; the Company’s growing commercial business, including ongo